NanoMab Technology has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta.
Privately held biopharmaceutical company, NanoMab Technology, has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta, it was revealed in an Oct. 27, 2020 press release.
The heads of terms outline the route toward a strategic alliance and supply agreement between the companies that will target the development of Rhenium-188 API solutions. Rhenium-188 API solutions are suitable for NanoMab’s range of nanobodies for the production of therapeutic radiopharmaceuticals.
“This is an important step for us in our development of cancer therapies,” said Dr. Hong Hoi Ting, NanoMab’s chief scientific officer, in the press release. “Ensuring that we have a global supply of Rhenium-188 is critical to our development plan and we are therefore delighted to be forming a partnership with such a high-quality company as OncoBeta.”
Nicholas H. Vetter, OncoBeta’s chief operating officer, added in the press release, “We have been impressed with NanoMab’s ambitious program to develop a range of radiopharmaceuticals for the treatment of a number of cancers. We’re delighted to work towards forming a partnership with NanoMab around the use of Rhenium-188 for further therapeutic purposes.”
Source: NanoMab
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.